Bone Marrow Transplantation

Papers
(The H4-Index of Bone Marrow Transplantation is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?218
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards130
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P613-P616)80
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO006)73
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P611-P612)65
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: statistical symposium-poster session (P188–P189)61
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)59
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group - Oral Session (O170-O171)57
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany54
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study52
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study52
High level serum IL-6 predicts occurrence of TA-TMA51
Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T46
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients45
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation42
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning42
Graft engineering: how long can you wait, how low can you go, and pandemic readiness42
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide41
Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation40
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee39
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P754-P757)38
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards37
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)36
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P183-P186)35
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P758-P762)35
Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients34
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse33
The effect of danger-associated molecular patterns on survival in acute graft versus host disease32
Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopo31
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma29
Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm29
In memory of Kristin Page 1974–202429
0.22087907791138